MarginsXMarginsX
Home › Markets › Health Care › VRAX

Virax Biolabs Group Limited (VRAX)

VRAX trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4480
-26.87% on the day
Market cap
$603K
Nano cap
Revenue · 2025
$12K
+96.2% on 2024
Net income · 2025
-$5.0M
-40439.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1885827/000119312526295158/0001193125-26-295158-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31.

Profile

FieldValue
TickerVRAX on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited Kingdom
IPO year2022
SEC CIK0001885827

Financials · 2025

LineValue
Revenue$12K
Net income-$5.0M
Operating income-$6.4M
Net margin-40439.1%
Operating margin-51515.2%
Revenue growth+96.2%
Cash$6.4M
Total assets$8.3M
P/E (computed)Net income was not positive
P/S (computed)48.5×

Warning signs

Cash runway
16.7 months
$6.4M cash at March 31, 2026
Share count, 1 year
+233.5%
2025-03-31 to 2026-03-31 · +831.4% over 3 years
Going-concern doubt
Yes
20-F filed July 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As discussed in Note 1 to the consolidated financial statements, the Company's significant operating losses raise substantial doubt about its ability to continue as a going concern."
20-F 2026-07-06
Cash and burn$6.4M cash; operating cash flow -$1.2M a quarter.Report 2026-03-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-03-31
Reverse splits, 3 years2; latest 1-for-25 on 2026-06-26Source 2026-06-26
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-09-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorReliant CPA PC, Newport Beach, California, United StatesPCAOB Form AP 2026-07-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
$12K-$5.0M-$4.6M$6.4MNo debt tags$12K20-F 2026-07-06
FY 2025
2025-03-31
$6K-$6.1M-$4.6M$4.2MNo debt tags$6K20-F 2025-07-02
FY 2024
2024-03-31
$156K-$6.7M-$6.2M$3.6MNo debt tags$156K20-F 2025-07-02
FY 2023
2023-03-31
$9K-$5.5M-$4.2M$9.4MNo debt tags$9K20-F 2025-07-02
FY 2022
2022-03-31
$0-$1.7M-$809K$22KNo debt tags$020-F 2024-08-20
FY 2021
2021-03-31
$124K-$651K-$590K$18KNo debt tags$124K20-F 2022-08-12

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-22.6%
1 month-64.7%
3 months-78.3%
Year to date-92.9%
1 year-94.9%
From 52-week high-96.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
QCLSQ/C Technologies Inc.$0.3210+4.80%$2.6M
TRIBTrinity Biotech plc$5.38-11.89%$4.4M
CDIOCardio Diagnostics Holdings Inc.$1.79-7.26%$5.3M
BMRABiomerica Inc.$1.32-2.94%$6.1M
VNRXVolitionRX Limited$0.1998-13.13%$7.2M
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
ICCCImmuCell Corporation$11.42+6.23%$103.8M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier